Effect of Blood Pressure Augmentation on CVA Patients who are out of Injection TPA (Tissue Plasminogen Activator) and Mechanical Thrombectomy Window

Main Article Content

Muhammad Waqas Ahmed Qureshi
Muhammad Zafar Ali
Jahanzeb Liaqat
Rabia Parveen
Pir Mubassir Shah
Aamir Sajjad
Muhammad Farrukh Habib

Abstract

Background: Ischemic stroke is a leading cause of morbidity and mortality worldwide, prompting an urgent need for effective treatments outside the standard therapeutic window. With an estimated 6.5 million stroke-related deaths annually and a particular prevalence in the 18-49 age demographic, there is a substantial burden on healthcare systems. Intravenous thrombolysis and mechanical thrombectomy are time-sensitive treatments that are not universally accessible, highlighting the need for alternative strategies.


Objective: The study aimed to evaluate the efficacy of induced hypertension as a therapeutic intervention for ischemic stroke patients who are beyond the window for conventional reperfusion therapies.


Methods: This cross-sectional observational study was conducted at the Hyper Acute Stroke Unit (HASU) of PEMH, Rawalpindi. Over four months, 50 male patients who had suffered an ischemic stroke and were outside the therapeutic window for TPA and mechanical thrombectomy were recruited. Induced hypertension was achieved through intravenous administration of norepinephrine, titrated to maintain systolic blood pressure between 180-200 mmHg. Blood pressure was recorded at baseline, immediately before norepinephrine administration, and every 12 hours thereafter. Muscle power was assessed using the Medical Research Council (MRC) scale at 24-hour intervals over a 3-day observational period.


Results: The mean systolic blood pressure was 140±5.07 mmHg, and the mean diastolic blood pressure was 94.16±4.71 mmHg, with a mean patient age of 55±4.4 years. Following induced hypertension, 30 out of the 50 patients (60%) showed improvement in muscle power. Specifically, in Group 1 (6 patients with leg muscle weakness), 3 patients improved from an MRC scale of 2 to 3, and 1 patient improved from an MRC scale of 3 to 4. In Group 2 (15 patients with upper and lower limb weakness), 7 patients improved from an MRC scale of 2 to 3, and 4 patients improved from an MRC scale of 3 to 4. Similar improvements were observed in other groups, with overall improvements ranging from 37.5% to 80% within individual subgroups.


Conclusion: Induced hypertension via norepinephrine infusion appears to be a promising therapeutic strategy to improve muscle power in ischemic stroke patients who cannot receive standard reperfusion treatments. This intervention could potentially bridge the treatment gap for patients who present outside of the traditional therapeutic time frame.

Downloads

Download data is not yet available.

Article Details

How to Cite
Qureshi, M. W. A., Ali, M. Z., Liaqat, J., Parveen, R., Shah, P. M., Sajjad, A., & Habib, M. F. (2023). Effect of Blood Pressure Augmentation on CVA Patients who are out of Injection TPA (Tissue Plasminogen Activator) and Mechanical Thrombectomy Window. Journal of Health and Rehabilitation Research, 3(2), 655–663. https://doi.org/10.61919/jhrr.v3i2.145
Section
Articles
Author Biographies

Muhammad Waqas Ahmed Qureshi, Pak Emirates Military Hospital (PEMH) Rawalpindi

Resident Medicine

Muhammad Zafar Ali, Armed Forces Institute of Rehabilitation Medicine (AFIRM) Rawalpindi

Medical Specialist

Jahanzeb Liaqat, Pak Emirates Military Hospital (PEMH) Rawalpindi

Consultant Neurologist

Rabia Parveen, Pak Emirates Military Hospital (PEMH) Rawalpindi

Classified Medical Specialist

Pir Mubassir Shah, Pak Emirates Military Hospital (PEMH) Rawalpindi

Resident Neurology

Aamir Sajjad, Pak Emirates Military Hospital (PEMH) Rawalpindi

Resident Neurolo

Muhammad Farrukh Habib, National University Of Medical Sciences Islamabad.

Department of Public Health

References

Fantini S, Sassaroli A, Tgavalekos KT, Kornbluth J. Cerebral blood flow and autoregulation: current measurement techniques and prospects for noninvasive optical methods. Neurophotonics. 2016.

vanDijk JG, van Rossum IA, Thijs RD. Timing of Circulatory and Neurological Events in Syncope. Front Cardiovasc Med. 2020;7:36

Greene NH, Lee LA. Modern and Evolving Understanding of Cerebral Perfusion and Autoregulation. AdvAnesth. 2012.

Sodaei F, Shahmaei V. Identification of penumbra in acute ischemic stroke using multimodal MR imaging analysis: A case report study. Radiol Case Rep. 2020

Musuka TD, Wilton SB, Traboulsi M, Hill MD. Diagnosis and management of acute ischemic stroke: speed is critical. CMAJ. 2015 Sep 8;187(12):887-93. doi: 10.1503/cmaj.140355. Epub 2015

Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics, and Prevention. Circ Res. 2017 Feb 3

Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, Fisher M, Pandian J, Lindsay P. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. Int J Stroke. 2022

Feigin VL, Brainin M, Norrving B, et al. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International Journal of Stroke. 2022

Ekker MS, Verhoeven JI, Vaartjes I, Jolink WMT, Klijn CJM, de LeeuwFE.etell. Association of Stroke Among Adults Aged 18 to 49 Years With Long-term Mortality. JAMA. 2019

Yousufuddin M, Young N. Aging and ischemic stroke. Aging (Albany NY). 2019

Samai AA, Martin-Schild S. Sex differences in predictors of ischemic stroke: current perspectives. Vasc Health Risk Manag. 2015

Hossmann KA. The two pathophysiologies of focal brain ischemia: implications for translational stroke research. JCereb Blood Flow Metab. 2012.

da Silva Paiva L, Oliveira FR, de Alcantara Sousa LV, Dos Santos Figueiredo FW, de Sá TH, Adami F. Decline in Stroke Mortality Between 1997 and 2012 by Sex: Ecological Study in Brazilians Aged 15 to 49 Years. Sci Rep. 2019.

Tekle WG, Chaudhry SA, Fatima Z, Ahmed M, Khalil S, Hassan AE, Rodriguez GJ, Suri FK, Qureshi AI. Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment. J VascInterv Neurol. 2012

Reiff T, Barthel O, Ringleb PA, Pfaff J, Mundiyanapurath S. Safety of Mechanical Thrombectomy with Combined Intravenous Thrombolysis in Stroke Treatment 4.5 to 9 Hours from Symptom Onset. J Stroke Cerebrovasc Dis. 2020

McManus M, Liebeskind DS. Blood Pressure in Acute Ischemic Stroke. J Clin Neurol. 2016 Apr;12(2):137-46. doi: 10.3988/jcn.2016.12.2.137. Epub 2016

Regenhardt RW, Das AS, Stapleton CJ, Chandra RV, Rabinov JD, Patel AB, Hirsch JA, Leslie-Mazwi TM. Blood Pressure and Penumbral Sustenance in Stroke from Large Vessel Occlusion. Front Neurol. 2017

Lidington D, Kroetsch JT, Bolz S-S. Cerebral artery myogenic reactivity: the next frontier in developing effective interventions for subarachnoid hemorrhage. J Cereb Blood Flow Metab. (2018)

Liu X. Beyond the time window of intravenous thrombolysis: standing by or by stenting? Interv Neurol. 2012

Sit JW, Yip VY, Ko SK, Gun AP, Lee JS. A quasi-experimental study on a community-based stroke prevention programme for clients with minor stroke. J ClinNurs. 2007

Shin HK, Nishimura M, Jones PB, Ay H, Boas DA, Moskowitz MA, Ayata C. Mild induced hypertension improves blood flow and oxygen metabolism in transient focal cerebral ischemia. Stroke. 2008

Koenig MA, Geocadin RG, De Grouchy M, Glasgow J, Vimal S, Restrepo L, Wityk RJ. Safety of induced hypertension therapy in patients with acute ischemic stroke. Neurocritical care. 2006 Feb;4:3-7.

Herpich F, Rincon F. Management of acute ischemic stroke. Critical care medicine. 2020 Nov;48(11):1654.

Most read articles by the same author(s)

1 2 3 4 > >>